NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased PROC...


NEW YORK, Aug.  13, 2026  (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.  If you suffered a loss on your Procept investments, you have until September 22, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.  Follow the link below for more information about the lawsuit:  [CONTACT THE FIRM IF YOU SUFFERED A LOSS]  What Is The Lawsuit About?  The lawsuit has been filed on behalf of investors who purchased securities during the period of February 28, 2024 and February 25, 2026, inclusive (“the Class Period”). The lawsuit alleges that Procept made materially false and misleading statements and/or failed to disclose: (i) that during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated the Company’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of the foregoing, Defendants’ representations during the Class Period regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.  On August 6, 2025, Procept announced earnings results for its second fiscal quarter of 2025, revealing that handpiece unit shipments had unexpectedly deteriorated as the Company has sold approximately 12,750 handpieces in the U.S. during the quarter. That same day, Procept announced it expected to ship 13,350 units the following quarter, down from consensus estimates of over 13,840 units. Additionally, CEO Reza Zadno announced that Procept was eliminating the role of Chief Commercial Officer. On this news, Procept’s stock price fell from $45.69 per share on August 6, 2025 to close at $38.41 per share on August 8, 2025, a decline of approximately 16%.  On November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that the Company had sold 13,225 handpieces, missing the Company’s guidance set during the previous quarter. The Company also announced it was reducing its annual handpiece sales guidance by 1,000 units, from 53,000 to 52,000 units. On this news, Procept’s stock price fell from $35.02 per share on November 4, 2025 to close at $31.30 per share on November 6, 2026, a decline of over 10%.  On February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year, revealing that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential that had grown over time, resulting in cumulative excess field inventory of over 10,000 units. As a result, Procept handpiece unit sales in the U.S. declined from 13,225 units in the third quarter to 9,400 units in the fourth quarter, a nearly 30% decline. On this news, Procept’s stock price fell over two trading days, from $27.84 per share on February 25, 2026 to close at $22.69 per share on February 27, 2026, a decline of over 18%.  [CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]  What Should I Do?  If you purchased or otherwise acquired Procept securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.  [HOW CAN I PROTECT MY RIGHTS?]  Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.  This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.  ContactsKirby McInerney LLP        Lauren Molinaro, Esq.212-699-1171https://www.kmllp.comhttps://securitiesleadplaintiff.com/investigations@kmllp.com  
            

PRCT

PRCT SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of PROCEPT BioRobotics Corporation Investors - Contact Kirby McInerney LLP by September 22, 2026

Procept Faces Securities Class Action Over Undisclosed Discounts and Revenue Risk

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased PROC...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>A securities-fraud class action accuses Procept of using an undisclosed discount program to push bulk handpiece orders, inflating U.S. sales and inventory. The Class Period spans Feb 28, 2024 to Feb 25, 2026, with a lead plaintiff deadline of Sept 22, 2026. The suit cites deteriorating shipments, updated guidance, and a large excess-inventory issue as indicators of potential material harm.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Procept faces securities class action alleging undisclosed discounts inflating sales.</li><li>Class period Feb 28, 2024–Feb 25, 2026; lead plaintiff deadline Sept 22, 2026.</li><li>Q2 2025 shipments 12,750; next quarter guided 13,350 vs consensus 13,840.</li><li>Q3 2025 shipments 13,225; guidance cut by 1,000 to 52,000 units; stock fell.</li><li>Feb 25, 2026: excess field inventory &gt;10,000; Q4 handpiece sales 9,400.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Procept BioRobotics Corporation (PRCT)</strong>: Subject of securities class action alleging undisclosed discount program inflated U.S. handpiece sales; potential material impact on perception and valuation.</li><li><strong>Kirby McInerney LLP (KM LLP)</strong>: Plaintiff law firm leading the securities class action; not a market participant but indicates filing activity and investor outreach.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a securities litigation filing against PRCT, highlighting potential regulatory and disclosure-risk implications rather than core operations or earnings.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal risk could drive near-term PRCT price volatility absent new material facts.</li><li>Lead plaintiff deadline of Sept 22, 2026 may spur trading activity and additional filings.</li><li>No immediate cash-flow impact unless a settlement or judgment occurs.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Procept BioRobotics Corporation, NASDAQ: PRCT.</li><li>Class Period: Feb 28, 2024–Feb 25, 2026.</li><li>Lead plaintiff deadline: Sept 22, 2026.</li><li>Q2 2025: shipments 12,750; next quarter guided 13,350 vs consensus 13,840.</li><li>Q3 2025: shipments 13,225; annual guidance reduced by 1,000 to 52,000.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term risk for PRCT headlines-driven volatility; valuation remains uncertain until settlement or clarity on disclosures.</p>
  </section>
</section>


<article>
  <h2>PRCT SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of PROCEPT BioRobotics Investors</h2>

  <section aria-label="Executive summary">
    <p>The securities fraud class action against PROCEPT BioRobotics Corporation, ticker <strong>PRCT</strong>, alleges that the company made materially false and misleading statements and/or failed to disclose critical information during the Class Period. Investors who purchased PROCEPT securities between <strong>February 28, 2024</strong> and <strong>February 25, 2026</strong> may seek to participate in the lawsuit. Lead plaintiff appointment must be requested by <strong><em>September 22, 2026</em></strong>, and eligible investors are encouraged to contact Kirby McInerney LLP for rights and interests in the action at no cost. This development was announced in connection with the securities fraud class action filed on behalf of PROCEPT investors (NASDAQ: PRCT), with additional details available from the law firm’s investigations team.</p>
  </section>

  <section aria-label="Lawsuit overview">
    <h3>What The Lawsuit Claims About PROCEPT PRCT</h3>
    <p>The lawsuit has been filed on behalf of investors who purchased securities during the period of <strong>February 28, 2024</strong> and <strong>February 25, 2026</strong>, inclusive (“the Class Period”). The lawsuit alleges that Procept made materially false and misleading statements and/or failed to disclose:</p>
    <ul>
      <li>that during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand;</li>
      <li>that Procept’s undisclosed discount program had artificially and unsustainably inflated the Company’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods;</li>
      <li>that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time;</li>
      <li>that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period;</li>
      <li>that, as a result of the foregoing, Defendants’ representations during the Class Period regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated;</li>
      <li>that, as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and</li>
      <li>that, as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.</li>
    </ul>

    <p>On <strong>August 6, 2025</strong>, Procept announced earnings results for its second fiscal quarter of 2025, revealing that handpiece unit shipments had unexpectedly deteriorated as the Company has sold approximately <strong>12,750</strong> handpieces in the U.S. during the quarter. That same day, Procept announced it expected to ship <strong>13,350</strong> units the following quarter, down from consensus estimates of over <strong>13,840</strong> units. Additionally, CEO Reza Zadno announced that Procept was eliminating the role of Chief Commercial Officer. On this news, Procept’s stock price fell from <strong>$45.69</strong> per share on August 6, 2025 to close at <strong>$38.41</strong> per share on August 8, 2025, a decline of approximately <strong>16%</strong>.</p>

    <p>On <strong>November 4, 2025</strong>, Procept announced earnings results for its third fiscal quarter of 2025, revealing that the Company had sold <strong>13,225</strong> handpieces, missing the Company’s guidance set during the previous quarter. The Company also announced it was reducing its annual handpiece sales guidance by 1,000 units, from <strong>53,000</strong> to <strong>52,000</strong> units. On this news, Procept’s stock price fell from <strong>$35.02</strong> per share on November 4, 2025 to close at <strong>$31.30</strong> per share on November 6, 2026, a decline of over <strong>10%</strong>.</p>

    <p>On <strong>February 25, 2026</strong>, Procept announced earnings results for its fourth fiscal quarter and year, revealing that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential that had grown over time, resulting in cumulative excess field inventory of over <strong>10,000</strong> units. As a result, Procept handpiece unit sales in the U.S. declined from <strong>13,225</strong> units in the third quarter to <strong>9,400</strong> units in the fourth quarter, a nearly <strong>30%</strong> decline. On this news, Procept’s stock price fell over two trading days, from <strong>$27.84</strong> per share on February 25, 2026 to close at <strong>$22.69</strong> per share on February 27, 2026, a decline of over <strong>18%</strong>.</p>
  </section>

  <section aria-label="What should investors do">
    <h3>What Should I Do As an Investor in PRCT?</h3>
    <p>If you purchased or otherwise acquired Procept securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.</p>

    <ul>
      <li><strong>Deadline for lead plaintiff applications:</strong> <em>September 22, 2026</em></li>
      <li>Learn more about the lead plaintiff process and eligibility requirements by visiting the firm’s site and the class action information page.</li>
    </ul>

    <p>Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.</p>

    <p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p>

    <h4>Contacts</h4>
    <ul>
      <li>Kirby McInerney LLP — Lauren Molinaro, Esq. — <a href="tel:2126991171">212-699-1171</a></li>
      <li>Website: <a href="https://www.kmllp.com">https://www.kmllp.com</a></li>
      <li>Investigations: <a href="https://securitiesleadplaintiff.com/investigations@kmllp.com">https://securitiesleadplaintiff.com/investigations@kmllp.com</a></li>
    </ul>
  </section>

  <section aria-label="Firm and company background">
    <h3>About PROCEPT BioRobotics Corporation and PRCT</h3>
    <p>PROCEPT BioRobotics Corporation is publicly traded under the ticker <strong>PRCT</strong> on NASDAQ. The class action concerns alleged misstatements and undisclosed risks impacting investors who purchased PROCEPT securities during the specified Class Period.</p>
  </section>
</article>

A securities-fraud class action accuses Procept of using an undisclosed discount program to push bulk handpiece orders, inflating U.S. sales and inventory. The Class Period spans Feb 28, 2024 to Feb 25, 2026, with a lead plaintiff deadline of Sept 22, 2026. The suit cites deteriorating shipments, updated guidance, and a large excess-inventory issue as indicators of potential material harm.

prct-shareholder-alert-securities-fraud-lawsuit-filed-on-behalf-of-procept-biorobotics-corporation-investors-contact-kirby-mcinerney-llp-by-september-22-2026

News insight

PRCT SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of PROCEPT BioRobotics Corporation Investors - Contact Kirby McInerney LLP by September 22, 2026

AI summary

Sentiment rationale

Key facts

Legal